Skip to main content
TipRanks
Go Ultimate75% OFF

BioAge Labs, Inc. (BIOA) Stock Price & Analysis

160 Followers

BIOA Stock Chart & Stats

$5.22-$0.33(-5.95%)
At close: 4:00 PM EST
$5$7.5$10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$5.08 - $5.67
52-Week Range
$4.81 - $25.96
Previous Close
$5.55
Volume
N/A
Average Volume (3M)
819.79K
Market Cap
$239.90M
Enterprise Value
$44.61M
Total Cash (Recent Filing)
$283.64M
Total Debt (Recent Filing)
$2.73M
Price to Earnings (P/E)
―
Beta
1.85
Next Earnings
Mar 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage gives BioAge financial flexibility while it advances clinical programs and absorbs operating losses. The limited debt burden reduces refinancing pressure and preserves more strategic options than a similarly unprofitable biotech carrying substantial borrowings.

Clinical Pipeline Progress

Progressing BGE-102 into Phase 2 creates a more developed clinical asset and provides defined milestones for assessing efficacy in diabetic macular edema. The trial may also guide expansion into other NLRP3-driven retinal diseases, supporting broader pipeline value.

BGE-102 Differentiation

The reported pharmacologic activity, tolerability, and tissue penetration support a potentially differentiated profile for BGE-102. A once-daily oral approach addressing several inflammatory pathways could broaden its usefulness if later-stage studies confirm these early findings.

Bears Say

Heavy Cash Burn

Deeply negative operating and free cash flow indicate that BioAge is not yet funding its activities internally. Continued clinical investment therefore depends on its existing resources or external financing, creating pressure to improve operating losses before cash consumption materially weakens flexibility.

Persistent Large Losses

Repeated and widening losses show that profitability remains distant and that the business is still consuming capital to support development. If this pattern continues, cumulative losses can erode the equity base and reduce the resources available for advancing multiple programs.

Weak Revenue Base

A small and declining revenue base provides limited support for BioAge’s substantial research and development spending. Although gross profit is high, operating expenses overwhelm it, leaving the company dependent on financing and future clinical success rather than current commercial earnings.

BioAge Labs, Inc. News

BIOA FAQ

What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $4.81 and its highest was $25.96 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $239.90M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s next earnings report is estimated for Mar 25, 2027 (not yet confirmed), which is in 128 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Nov 05, 2026. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.635 by -$0.095.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.74.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 45,958,508 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.635. Following the earnings report the stock price went down -3.61%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Hedge funds hold BioAge Labs, Inc. shares: the largest hedge-fund position in BioAge Labs, Inc. is 72,324,513 shares, and hedge funds increased their holdings by 601.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology